Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings - PubMed (original) (raw)
Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings
Maren Hermanns-Clausen et al. Addiction. 2013 Mar.
Abstract
Aims: Recently, several synthetic cannabinoids were identified in herbal mixtures consumed as recreational drugs alternative to cannabis products. The aim was to characterize the acute toxicity of synthetic cannabinoids as experienced by emergency patients.
Design: This was a retrospective study targeting patients seeking emergency treatment after recreational use of synthetic cannabinoids.
Setting and participants: Patients were selected from the database of the Poisons Information Center Freiburg between September 2008 and February 2011. The inclusion criteria were: hospitalization, available clinical reports and analytical verification of synthetic cannabinoid uptake. In total, 29 patients were included (age 14-30 years, median 19; 25 males, four females).
Measurements: Clinical reports were evaluated and synthetic cannabinoids and other drugs were determined analytically.
Findings: CP-47,497-C8 (one), JWH-015 (one), JWH-018 (eight), JWH-073 (one), JWH-081 (seven), JWH-122 (11), JWH-210 (11), JWH-250 (four) and AM 694 (one) were quantified in blood samples. JWH-018 was most common in 2008-9, JWH-122 in 2010, and JWH-210 in 2011. Tachycardia, agitation, hallucination, hypertension, minor elevation of blood glucose, hypokalaemia and vomiting were reported most frequently. Chest pain, seizures, myoclonia and acute psychosis were also noted.
Conclusions: There appears to have been an increase in use of the extremely potent synthetic cannabinoids JWH-122 and JWH-210. Acute toxic symptoms associated with their use are also reported after intake of high doses of cannabis, but agitation, seizures, hypertension, emesis and hypokalaemia seem to be characteristic to the synthetic cannabinoids, which are high-affinity and high-efficacy agonists of the CB(1) receptor. Thus, these effects are due probably to a strong CB(1) receptor stimulation.
© 2012 The Authors, Addiction © 2012 Society for the Study of Addiction.
Comment in
- Commentary on Hermanns-Clausen et al. (2013): Spicing things up--the emerging phenomenon of synthetic cannabinoid use.
Addy PH, Cyril D'Souza D. Addy PH, et al. Addiction. 2013 Mar;108(3):545-6. doi: 10.1111/add.12098. Addiction. 2013. PMID: 23418659 No abstract available.
Similar articles
- Adverse effects after the use of JWH-210 - a case series from the EU Spice II plus project.
Hermanns-Clausen M, Kithinji J, Spehl M, Angerer V, Franz F, Eyer F, Auwärter V. Hermanns-Clausen M, et al. Drug Test Anal. 2016 Oct;8(10):1030-1038. doi: 10.1002/dta.1936. Epub 2016 Jan 15. Drug Test Anal. 2016. PMID: 26768345 - Toxicological findings of synthetic cannabinoids in recreational users.
Kronstrand R, Roman M, Andersson M, Eklund A. Kronstrand R, et al. J Anal Toxicol. 2013 Oct;37(8):534-41. doi: 10.1093/jat/bkt068. Epub 2013 Aug 22. J Anal Toxicol. 2013. PMID: 23970540 - The "new" marijuana.
Wells DL, Ott CA. Wells DL, et al. Ann Pharmacother. 2011 Mar;45(3):414-7. doi: 10.1345/aph.1P580. Epub 2011 Feb 15. Ann Pharmacother. 2011. PMID: 21325097 Review. - [Pharmacological properties and dependence liabilities of synthetic cannabinoids].
Funada M. Funada M. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2010 Jun;45(3):167-74. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2010. PMID: 20681249 Review. Japanese.
Cited by
- Psychosis associated with acute recreational drug toxicity: a European case series.
Vallersnes OM, Dines AM, Wood DM, Yates C, Heyerdahl F, Hovda KE, Giraudon I; Euro-DEN Research Group; Dargan PI. Vallersnes OM, et al. BMC Psychiatry. 2016 Aug 18;16:293. doi: 10.1186/s12888-016-1002-7. BMC Psychiatry. 2016. PMID: 27538886 Free PMC article. - Combination Chemistry: Structure-Activity Relationships of Novel Psychoactive Cannabinoids.
Wiley JL, Marusich JA, Thomas BF. Wiley JL, et al. Curr Top Behav Neurosci. 2017;32:231-248. doi: 10.1007/7854_2016_17. Curr Top Behav Neurosci. 2017. PMID: 27753007 Review. - Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants.
Miliano C, Serpelloni G, Rimondo C, Mereu M, Marti M, De Luca MA. Miliano C, et al. Front Neurosci. 2016 Apr 19;10:153. doi: 10.3389/fnins.2016.00153. eCollection 2016. Front Neurosci. 2016. PMID: 27147945 Free PMC article. Review. - Clinical Effects of Synthetic Cannabinoid Receptor Agonists Compared with Marijuana in Emergency Department Patients with Acute Drug Overdose.
Zaurova M, Hoffman RS, Vlahov D, Manini AF. Zaurova M, et al. J Med Toxicol. 2016 Dec;12(4):335-340. doi: 10.1007/s13181-016-0558-4. Epub 2016 Jun 2. J Med Toxicol. 2016. PMID: 27255136 Free PMC article. - A Curious Case of Inhalation Fever Caused by Synthetic Cannabinoid.
Chinnadurai T, Shrestha S, Ayinla R. Chinnadurai T, et al. Am J Case Rep. 2016 Jun 5;17:379-83. doi: 10.12659/ajcr.898500. Am J Case Rep. 2016. PMID: 27262587 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous